After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Viatris was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.

Viatris (NASDAQ: VTRS) started trading publicly via a spinoff-merger. Ever since, the stock has been underperforming due to selling pressure.

Viatris, the drugmaker previously known as Mylan, announced on Monday that it had agreed to pay $264 million to settle a class-action lawsuit that alleged the company was involved in an illegal ...